MedTrace Logo

Immune Modulation by Exosomes in COVID-19

NCT05191381 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-01-17

No results posted yet for this study

Summary

Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.

Conditions

Interventions

BIOLOGICAL

Application of exosomes in a whole blood assay

Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.

Sponsors & Collaborators

  • University of Ulm

    lead OTHER

Principal Investigators

  • Manfred Weiss, MD · Clinic of Anaesthesiology and Intensive Care Medicine

  • Marion Schneider, PhD · Clinic of Anaesthesiology and Intensive Care Medicine

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-22
Primary Completion
2025-07-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05191381 on ClinicalTrials.gov